SCHEMBL21724658

SCHEMBL21724658

CCCCCCCC(=O)NC(CC(N)=O)C(=O)NC(CC(C)C)C(=O)OC

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BIRC2 Q13490 3/20 0.55
PLA2G10 O15496 2/20 0.49
FOLH1 Q04609 1/20 0.47
MEN1 O00255 1/20 0.44
FAAH O00519 1/20 0.44
MAPK1 P28482 1/20 0.44
KMT2A Q03164 1/20 0.44
PSMB5 P28074 2/20 0.43
PRSS1 P07477 1/20 0.43
FURIN P09958 1/20 0.43
PLA2G2A P14555 2/20 0.42
PLA2G5 P39877 2/20 0.42
PTPN1 P18031 1/20 0.41
NOD1 Q9Y239 2/20 0.41
DNM1 Q05193 1/20 0.41
TLR2 O60603 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21724656 1.00 BIRC2 (0.55) BIRC2PLA2G10FOLH1MEN1FAAH
SCHEMBL21724524 0.88 BIRC2 (0.51) BIRC2PLA2G10MEN1FAAHMAPK1
SCHEMBL21724505 0.88 BIRC2 (0.51) BIRC2PLA2G10MEN1FAAHMAPK1
SCHEMBL21732832 0.88 BIRC2 (0.51) BIRC2PLA2G10MEN1FAAHMAPK1
SCHEMBL21724526 0.88 BIRC2 (0.51) BIRC2PLA2G10MEN1FAAHMAPK1
SCHEMBL21724226 0.88 BIRC2 (0.51) BIRC2PLA2G10MEN1FAAHMAPK1
SCHEMBL21724147 0.88 BIRC2 (0.51) BIRC2PLA2G10MEN1FAAHMAPK1
SCHEMBL21724149 0.88 BIRC2 (0.51) BIRC2PLA2G10MEN1FAAHMAPK1
SCHEMBL21724145 0.88 BIRC2 (0.51) BIRC2PLA2G10MEN1FAAHMAPK1
SCHEMBL8616354 0.87 KMT2A (0.57) BIRC2PLA2G10FOLH1MEN1FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240398966-A1 CONJUGATES AND METHODS OF USING THE SAME FLAGSHIP PIONEERING INNOVATIONS V INC (US) 2024-12-05 US disclosed
US-11998610-B2 Conjugates and methods of using the same FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2024-06-04 US disclosed
EP-3836971-A1 CONJUGATES AND METHODS OF USING THE SAME Flagship Pioneering Innovations V, Inc. (US) 2021-06-23 EP disclosed
US-20210162057-A1 CONJUGATES AND METHODS OF USING THE SAME FLAGSHIP PIONEERING INNOVATIONS V, INC. 2021-06-03 US disclosed
WO-2020037009-A1 CONJUGATES AND METHODS OF USING THE SAME FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2020-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11998610-B2 Conjugates and methods of using the same CD47, CD44, CD74 BIRC2 1554/4885PLA2G10 786/4885FOLH1 12/4885
US-20210162057-A1 CONJUGATES AND METHODS OF USING THE SAME CD47, CD44, CD74 BIRC2 1554/4885PLA2G10 786/4885FOLH1 12/4885
US-20240398966-A1 CONJUGATES AND METHODS OF USING THE SAME CD47, CD44, CD74 BIRC2 1554/4885PLA2G10 786/4885FOLH1 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.